Free Helpline
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Compare Mavyret and Epclusa, two powerful antiviral treatments for Hepatitis C. Learn about their uses, effectiveness, side effects, drug interactions, and cost.
If you've been diagnosed with Hepatitis C, you might be feeling a mix of concern and a desire to find the best treatment. It's a common infection that affects the liver, caused by the Hepatitis C virus (HCV). Fortunately, advancements in medicine have given us highly effective antiviral medications to combat this virus. Two such medications that doctors often consider are Mavyret and Epclusa. Both are powerful tools in the fight against Hepatitis C, but they do have their differences. Understanding these distinctions can empower you to have a more informed discussion with your healthcare provider and choose the path that's best for your unique situation.
Before we dive into the specifics of Mavyret and Epclusa, let's briefly touch upon Hepatitis C itself. It's a viral infection that primarily targets the liver. When the virus enters your body, it can lead to inflammation of the liver, which, if left untreated for a long time, can cause serious liver damage, including cirrhosis (scarring) and even liver cancer. Hepatitis C is typically spread through contact with infected blood, often through sharing needles or other drug-injection equipment, though it can also be transmitted through sexual contact or from mother to baby during pregnancy. Thankfully, with timely diagnosis and treatment, Hepatitis C is often curable.
Mavyret and Epclusa are both prescription antiviral medications designed to treat chronic Hepatitis C. They belong to a class of drugs known as direct-acting antivirals (DAAs), which work by blocking the virus's ability to multiply and spread within your body. Think of them as highly targeted agents that go straight for the virus, preventing it from causing further harm.
Mavyret is a combination medication containing two active ingredients: glecaprevir and pibrentasvir. It's known for its effectiveness across a broad range of Hepatitis C genotypes (strains of the virus).
Similarly, Epclusa is also a combination drug, featuring velpatasvir and sofosbuvir as its active components. It too is highly effective against several common Hepatitis C genotypes.
Both Mavyret and Epclusa are prescribed to help cure chronic Hepatitis C in adults. The specific genotypes and conditions they treat can vary slightly:
While both medications aim to cure Hepatitis C, understanding their differences is key to making an informed choice:
One significant difference lies in the typical duration of treatment. Mavyret often offers a shorter treatment course, commonly 8 weeks for many patients, depending on the genotype and whether they have cirrhosis. Epclusa's treatment duration is usually 12 weeks, though this can also vary.
Both are broad-spectrum, meaning they cover multiple genotypes. However, Mavyret is specifically noted for its effectiveness across genotypes 1 to 6, including cases previously treated without success. Epclusa also covers genotypes 1 to 6.
Both are approved for children aged 3 and older. However, the specific indications for children can differ slightly, particularly regarding previous treatment failures or the presence of severe cirrhosis, where Epclusa might be used with ribavirin.
This is a significant consideration for many patients. Mavyret is exclusively a brand-name drug and does not have a generic version available. Epclusa, on the other hand, does have a generic version. Generic medications are typically less expensive than their brand-name counterparts, which can make a substantial difference in out-of-pocket costs for patients. If cost is a major concern, discussing the availability and suitability of generic Epclusa with your doctor is a wise step.
Like all medications, Mavyret and Epclusa can cause side effects. It's important to remember that not everyone experiences them, and many are mild and temporary. Always discuss any concerns with your doctor.
It's essential to report any severe or persistent side effects to your doctor immediately. Your doctor will monitor your liver function throughout the treatment period.
This is a critical area where caution is needed. Both Mavyret and Epclusa can interact with a number of other medications. These interactions can potentially affect how well the Hepatitis C drugs work or increase the risk of side effects from either drug. It is absolutely vital to provide your doctor with a complete list of all medications, supplements, and herbal products you are taking before starting treatment.
Mavyret has additional interactions that your doctor will consider. Always have an up-to-date list of your medications handy.
The cost of Hepatitis C treatments can be substantial. Both Mavyret and Epclusa are expensive medications. However, the cost you ultimately pay will depend on several factors:
Don't hesitate to discuss financial concerns with your doctor or a patient assistance program representative. Many manufacturers offer programs to help reduce the cost for eligible patients.
Deciding between Mavyret and Epclusa isn't a decision you make alone. It's a collaborative process with your healthcare provider. Here’s a practical approach:
Real-Life Scenario: Priya, a 45-year-old homemaker, was recently diagnosed with Hepatitis C genotype 3 without cirrhosis. Her doctor explained both Mavyret and Epclusa are options. Priya was concerned about the length of treatment and the cost, as she didn't have insurance. Her doctor explained Mavyret might offer an 8-week course, while Epclusa is typically 12 weeks. They also discussed the generic option for Epclusa, which Priya decided to explore further with the pharmacy to understand potential savings.
If you suspect you might have Hepatitis C, or if you have been diagnosed and haven't started treatment yet, it's time to see a doctor. Symptoms can be subtle or absent, making regular check-ups and blood tests important, especially if you fall into a higher-risk group.
Seek medical advice immediately if you experience:
A: Yes, both Mavyret and Epclusa are highly effective direct-acting antiviral medications that can cure chronic Hepatitis C in the vast majority of patients when taken as prescribed.
A: Neither drug is universally
Overall, early action and medically verified advice remain the safest approach.
Confused about whether CBD can get you high? Understand the difference between CBD and THC, their effects on your body, and what to look for in safe, non-intoxicating CBD products.
April 1, 2026
Learn about anticoagulants and antiplatelet drugs, often called blood thinners. Understand how they prevent blood clots, when they're prescribed, their side effects, and essential safety tips for Indian readers.
April 1, 2026
Confused about Plan B and abortion pills? Understand the key differences, how they work, and their effectiveness for informed reproductive health decisions.
April 1, 2026